Seattle’s Parse Biosciences to be Acquired by Qiagen for $225M

Seattle-based Parse Biosciences is being acquired by Qiagen in a $225M deal expected to close in December, a move that could accelerate breakthroughs in understanding and treating disease. Founded in 2018 at the University of Washington by Alex Rosenberg and Charles Roco, Parse pioneered single-cell RNA sequencing technology that helps scientists see how individual cells function and respond to treatment.